Researchers assessed long-term effectiveness and tolerability of brivaracetam in patients with focal epilepsy. According to this multicenter retrospective study, brivaracetam was effective and well-tolerated in a large population of patients with predominantly drug-resistant epilepsy. There were no unexpected adverse events (AEs) over 1 year. The most frequently reported AEs were somnolence, irritability and dizziness.
January 16, 2020
Systematic Review Highlights That Clinicians Should Be Aware of Possible Skin-related Drug Reactions to Levetiracetam
This study states that clinicians should be aware of the possible cutaneous adverse drug reactions induced by levetiracetam to avoid the development of a potentially fatal condition.
January 13, 2020
Taro Pharmaceuticals Press Release: Voluntary Nationwide Recall of Lamotrigine Tablets USP, 100 mg, 100 Count Bottles
Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling one (1) lot of Lamotrigine 100 mg Tablets, Lot # 331771 (expiration date June 2021) in 100 count bottles, NDC 51672-4131-1 to the consumer level. This single lot of